MA46945A - Exopolysaccharides et leurs utilisations - Google Patents

Exopolysaccharides et leurs utilisations

Info

Publication number
MA46945A
MA46945A MA046945A MA46945A MA46945A MA 46945 A MA46945 A MA 46945A MA 046945 A MA046945 A MA 046945A MA 46945 A MA46945 A MA 46945A MA 46945 A MA46945 A MA 46945A
Authority
MA
Morocco
Prior art keywords
exopolysaccharides
Prior art date
Application number
MA046945A
Other languages
English (en)
Inventor
Silvia Balzaretti
Andrea Biffi
Walter Fiore
Simone Domenico Guglielmetti
Ruggero Rossi
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MA46945A publication Critical patent/MA46945A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MA046945A 2016-12-02 2017-12-01 Exopolysaccharides et leurs utilisations MA46945A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000122724A IT201600122724A1 (it) 2016-12-02 2016-12-02 Exopolysaccharides and uses thereof

Publications (1)

Publication Number Publication Date
MA46945A true MA46945A (fr) 2021-03-17

Family

ID=58609750

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046945A MA46945A (fr) 2016-12-02 2017-12-01 Exopolysaccharides et leurs utilisations

Country Status (11)

Country Link
US (1) US11591416B2 (fr)
EP (1) EP3548630A1 (fr)
CN (1) CN110191957B (fr)
AU (2) AU2017367302B2 (fr)
BR (1) BR112019010867A2 (fr)
CL (1) CL2019001493A1 (fr)
CO (1) CO2019007116A2 (fr)
IT (1) IT201600122724A1 (fr)
MA (1) MA46945A (fr)
MX (1) MX2019006406A (fr)
WO (1) WO2018100549A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
CN114025778B (zh) * 2019-06-05 2024-04-12 Lac2生物群系有限公司 包含细菌菌株副干酪乳杆菌和透明质酸的组合物及其治疗皮肤的用途
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (fr) 2000-04-10 2001-10-17 Phillip Connolly Concentré de lactoprotéines amelioré
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
CN1627948A (zh) 2002-04-24 2005-06-15 麦迪卡博公司 治疗炎症性肠病的组合物和试剂盒
EP1530642B1 (fr) * 2002-08-06 2009-12-30 Danisco A/S Utilisation de lactobacillus pour produire des exopolysaccharides dans des produits alimentaires ou pharmaceutiques
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (fr) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Procedes et compositions permettant de detecter des microbes dans des echantillons fecaux
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
WO2005083122A2 (fr) 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Methode de detection de micro-organisme dans un echantillon fecal
US7510734B2 (en) 2004-03-04 2009-03-31 E-L Management Corporation Skin treatment method with Lactobacillus extract
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
CA2601427C (fr) 2005-04-06 2013-06-11 Novartis Ag Methode et composition pouvant ameliorer a des fins nutritionnelles la regulation de la glycemie et l'action de l'insuline
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
JP4590573B2 (ja) 2006-02-21 2010-12-01 国立大学法人富山大学 感染症起因菌の迅速同定方法
JP5289936B2 (ja) 2006-02-24 2013-09-11 キユーピー株式会社 新規な低分子ヒアルロン酸および／またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物
WO2007140621A1 (fr) 2006-06-09 2007-12-13 Nutravital Inc. Compositions probiotiques et leurs utilisations
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
CA2673120C (fr) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
EP1972208A1 (fr) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition pour améliorer la flore microbienne intestinale
BRPI0809454A2 (pt) 2007-03-27 2014-09-09 Procter & Gamble Métodos e kits para a administração de probióticos
BRPI0811451A2 (pt) * 2007-05-04 2014-11-04 Alimentary Health Ltd Exopolissacarídeo
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2173196B1 (fr) 2007-07-06 2011-02-16 N.V. Nutricia Utilisation de probiotiques et de fibres pour la diarrhée
US8193155B2 (en) 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
CN102089422B (zh) * 2008-07-11 2013-07-17 科.汉森有限公司 新的益生长双歧杆菌
WO2010008272A1 (fr) 2008-07-15 2010-01-21 N.V. Nutricia Traitement de troubles du transit intestinal
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
PT2403510T (pt) 2009-03-05 2020-04-02 Probiotical Spa Estirpes bacterianas com uma elevada actividade antiinflamatória
WO2010103132A1 (fr) 2009-03-10 2010-09-16 Hero España, S.A. Isolement, identification et caractérisation de souches ayant une activité probiotique à partir de fèces de nourrissons alimentés exclusivement avec du lait maternel
ES2660008T3 (es) 2009-09-23 2018-03-20 Thomas Julius Borody Terapia para infecciones entéricas crónicas
PH12012500687A1 (en) 2009-11-12 2012-10-29 Nestec Sa Nutritional composition for promoting gut microbiota balance and health
NZ600258A (en) 2009-12-22 2014-01-31 Probi Ab Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
ITUD20100112A1 (it) 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
WO2012135499A1 (fr) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Compositions nutritionnelles probiotiques pour l'activité sportive
WO2012154738A1 (fr) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition et procédé pour améliorer la santé intestinale
JP6329903B2 (ja) * 2011-09-23 2018-05-23 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 改変されたグラム陽性菌及びその使用
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
AU2014226633A1 (en) 2013-03-05 2015-09-03 Academisch Ziekenhuis Groningen Use of Faecali bacterium prausnitzii HTF-F (DSM 26943) to suppress inflammation.
AU2014286177B2 (en) 2013-07-02 2018-01-18 Austrianova Singapore Pte Ltd. A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containing freeze-dried encapsulated cells and uses of such cells and compositions
ITMI20131473A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
AU2015258769A1 (en) 2014-05-12 2016-12-01 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
EP2990045B1 (fr) 2014-08-26 2016-11-16 Chr. Hansen A/S Bifidobacterium animalis subsp. lactis destiné à être utilisé pour réduire la douleur abdominale chez une femme ménopausée
WO2017195182A1 (fr) 2016-05-13 2017-11-16 Sofar S.P.A. Utilisation de probiotiques pour améliorer l'absorption des protéines
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
US11207358B2 (en) 2016-12-16 2021-12-28 Compagnie Gervais Danone Probiotic composition comprising Lactobacillus rhamnosus and Lactobacillus paracasei and methods thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2019019961A1 (fr) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
KR102815561B1 (ko) 2017-12-06 2025-05-29 락2바이오메 에스.알.엘. 프로바이오틱스 조성물 및 그 용도
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine

Also Published As

Publication number Publication date
AU2022204885A1 (en) 2022-07-28
EP3548630A1 (fr) 2019-10-09
CN110191957B (zh) 2023-07-28
IT201600122724A1 (it) 2018-06-02
BR112019010867A2 (pt) 2019-10-22
US11591416B2 (en) 2023-02-28
US20190345268A1 (en) 2019-11-14
AU2017367302B2 (en) 2022-07-28
AU2017367302A1 (en) 2019-06-20
CL2019001493A1 (es) 2019-08-30
CO2019007116A2 (es) 2019-09-09
MX2019006406A (es) 2019-08-14
WO2018100549A1 (fr) 2018-06-07
CN110191957A (zh) 2019-08-30

Similar Documents

Publication Publication Date Title
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3732201A4 (fr) Molécules de substitution de wnt et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
EP3490565A4 (fr) Modulateurs de récepteurs de chimiokine et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3352776A4 (fr) Répresseurs htt et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations
EP3370528A4 (fr) Compositions probiotiques et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3347020A4 (fr) Acétamide thiénotriazoldiazépines et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations
EP3341007A4 (fr) Inhibiteurs de malt1 et leurs utilisations
MA46901A (fr) Agents psychotropes et leurs utilisations
EP3432859A4 (fr) Compositions cosmétiques et leurs utilisations
EP3664799A4 (fr) Antibiotiques linconsamides et leurs utilisations